Can āshibio’s andecaliximab stop abnormal bone growth? An 86.2% flare-up reduction raises the stakes
āshibio reports 86.2% fewer FOP flare-ups with andecaliximab in early data, but placebo-controlled evidence remains pending.
Pharma & Biotech